Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate

Internal Medicine Journal

Volumn 39, Issue 6, 2009, Pages 408-411

  Isobe, Y ^a   Sugimoto, K ^a   Masuda, A ^a   Hamano, Y ^a   Oshimi, K ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibroblast growth factor 23; Humoral hypercalcaemia; Neuroendocrine tumours; Parathyroid hormone related protein; Somatostatin analogues

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; IMATINIB; METHOTREXATE; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTERIAL MENINGITIS; BLAST CELL CRISIS; BLOOD BRAIN BARRIER; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG PENETRATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RETREATMENT;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 67650727223     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01947.x     Document Type: Article

References (13)

1. Tsao A, Kantarien H, Talpaz M. STI-571 in chronic myelogenous leukemia. Br J Haematol 2002 119 : 15 24.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarini M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 348 : 994 1004. (Pubitemid 36302244)
3. Inverardi D, Lazzarino M, Morra E, Bernasconi P, Merante S, Canevari A et al. Extramedullary disease in Ph'-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance. Haematologica 1990 75 : 146 8.
4. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HCH, Schneller F et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002 117 : 623 5.
5. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia in patients on imatinib therapy. Leuk Lymphoma 2004 45 : 401 3.
6. Rajappa S, Uppin SG, Raghunadharao D, Satishrao I, Surath A. Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol 2004 22 : 179 81.
7. Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M et al. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol 2005 81 : 307 9.
8. Simpson E, O'Brient SG, Reilly JT. Extramedullary blast crisis in CML patients in complete hematological remission treated with imatinib mesylate. Clin Lab Haemtol 2006 28 : 215 16.
9. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W et al. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukemia occurring during imatinib therapy. Eur J Clin Invest 2007 37 : 808 13.
10. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 22 : 935 42.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 2 : 561 6.
12. Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003 101 : 5010 13.
13. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003 304 : 1085 92.